New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
18:27 EDTADBE, MCRS, FLXN, SUNE, LZB, ECYT, GWPH, ZBRAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Adobe (ADBE), up 9% after reporting better than expected quarterly results. ALSO HIGHER: MICROS Systems (MCRS), up 1.8%... Flexion Therapeutics (FLXN), up 1.32% after announcing positive topline results from its Phase 2a pharmacokinetic trial... Sunedison (SUNE), up 1.35%. DOWN AFTER EARNINGS: La-Z-Boy (LZB), down 10.23% after reporting fourth quarter revenue below expectations. ALSO LOWER: Endocyte (ECYT), down 18.13% after announcing that Merck (MRK) will no longer pursue development of vintafolide... GW Pharmaceuticals (GWPH), down 5.25%... Zebra Technologies (ZBRA), down 4.6%.
News For ADBE;MCRS;FLXN;SUNE;LZB;ECYT;GWPH;ZBRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
08:43 EDTSUNESunEdison upgraded to Outperform at Cowen
Subscribe for More Information
06:40 EDTSUNESunEdison upgraded to Outperform from Market Perform at Cowen
Price target to $24 from $20.
October 16, 2014
14:21 EDTSUNESunEdison volatility elevated on wide price movement
Subscribe for More Information
11:36 EDTSUNEOptions with increasing implied volatility
Options with increasing implied volatility: UVXY NQ PVA SVXY VXX SUNE CIE COV ZU CODE
07:37 EDTSUNESunEdison enters into PV project Joint Venture with JIC Capital
SunEdison has entered into a joint venture agreement with JIC Capital to facilitate nonrecourse financing and develop, construct and own up to 1 GW of utility-scale solar photovoltaic projects in China over the next 3 years.
October 15, 2014
13:01 EDTZBRAZebra Technologies announces Zatar reseller agreement with GainSpan
Subscribe for More Information
11:47 EDTADBEPublicis acquires 3 Share, financial terms not disclosed
After recently forming a partnership with Adobe (ADBE), Publicis (PUBGY) announces the acquisition of 3 SHARE. Based in San Diego, 3 SHARE is a partner in Adobe's Business Plus Level Solutions. 3 SHARE will operate as part of DigitasLBi.
11:46 EDTSUNEOptions with increasing implied volatility
Subscribe for More Information
07:40 EDTSUNESunEdison's Global Services Division surpasses 3 gigawatts of solar capacity
Subscribe for More Information
October 14, 2014
18:20 EDTGWPHOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTGWPHGW Pharmaceuticals CEO says market for Epidiolex may be expanded over time
Subscribe for More Information
14:55 EDTGWPHGW Pharma analyst day positive, reason for sell-off unclear, says Piper Jaffray
Subscribe for More Information
08:07 EDTGWPHGW Pharmaceuticals data should 'silence the doubters,' says Piper Jaffray
Subscribe for More Information
07:37 EDTSUNESunEdison announces zero white space solar module technology
Subscribe for More Information
07:15 EDTGWPHGW Pharmaceuticals says Epidiolex physician reports show signals of efficacy
Subscribe for More Information
07:11 EDTGWPHGW Pharmaceuticals announces preliminary topline results of Phase 2a trial
Subscribe for More Information
06:38 EDTGWPHGW Pharmaceuticals to host research and development day
Subscribe for More Information
October 8, 2014
11:23 EDTGWPHGW Pharmaceuticals slides after U.K. body recommends against use of Sativex
Subscribe for More Information
10:24 EDTGWPHGW Pharmaceuticals weakness on NICE guidance 'irrational,' says Piper Jaffray
Subscribe for More Information
10:04 EDTGWPHNICE guidance does not recommend use of Sativex in MS care
In an update to its original 2003 guideline, the U.K.'s National Institute for Health and Care Excellence has set out how people with multiple sclerosis, or MS, can receive better care. In the update, NICE recommends that people with suspected MS should be referred to a consultant neurologist. MS should not be diagnosed on the basis of MRI findings alone and only a consultant neurologist should make the diagnosis of MS. The guidance does not recommend the use of the cannabinoid drug Sativex, manufactured by GW Pharmaceuticals (GWPH), or fampridine as they provide only a modest benefit at a significant cost to the NHS, NICE stated. Shares of GW Pharmaceuticals are down 7% in early trading following the publication of NICE's new guidelines.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use